Circulating tumor DNA predicts neoadjuvant immunotherapy efficacy and recurrence-free survival in surgical non-small cell lung cancer patients.
Yue D, Liu W, Chen C, Zhang T, Ma Y, Cui L, Gu Y, Bei T, Zhao X, Zhang B, Bai Y, Romero A, Xu-Welliver M, Wang C, Zhang Z, Zhang B.
Yue D, et al. Among authors: chen c.
Transl Lung Cancer Res. 2022 Feb;11(2):263-276. doi: 10.21037/tlcr-22-106.
Transl Lung Cancer Res. 2022.
PMID: 35280315
Free PMC article.